We have a new job in the field of genetics , are you working in industry or
academia and looking for career progression ?:

1. Work closely with members of  Clinical Pharmacogenomics in
identifying study objectives and translating them into specific statistical
questions.
2.
a. These will typically be documented at a high level in the study
protocol and in some detail in the joint Pharmacogenomic (PG) and
Statistics analysis plan. Consideration should be given to power and sample
size, possible confounding variables, multiplicity issues and to the likely
presentation of results.
b. Careful consideration must be given to the source of data: clinical
trials, academic collaborators, de novo prospective studies, family
studies, etc. and whether study objectives can be met with the proposed
data.  Likewise, phenotype definition (clinical endpoint or case-control
definition) must also be given careful consideration.
c. Generally, this will involve some collaboration with the project
statistician assigned to the compound or therapeutic area, to ensure that
relevant information is shared in both directions.
d. Many studies are of the case-control type and much of the work is
exploratory in nature. It is essential to give clear advice about the
statistical aspects of such studies, both to the Clinical Pharmacogenomics
group and to other statisticians, whose experience typically does not
include the design and analysis of case-control studies.
3. Work closely with colleagues in Biostatistics & Reporting and in
Clinical Pharmacogenomics to ensure the implementation of the statistical
analyses described in the joint PG/B&R pharmacogenomic analysis plan,
together with such reasonable data-driven additional analyses as may be
agreed upon to facilitate sufficient understanding of the data.
a. Explanatory tables, listings and plots may be produced by
Statistical Programming support under guidance of the job-holder, or by the
job holder.
b. Statistical analyses may be conducted by the job-holder or, on
occasion, by a project statistician under guidance of the job-holder.
c. Whilst the analysis plan will have anticipated the major
statistical analyses to be undertaken, the work is typically of an
exploratory nature. The job-holder should remain aware of the study
objectives and should advise about the suitability and the sufficiency of
the analyses undertaken or proposed throughout the reporting phase.
d. Ensure that the Clinical Pharmacogenomic study report contains
relevant and correct statistical information, contributing relevant
sections and reviewing the contribution of other statisticians where
necessary.
4. Work closely with Clinical Pharmacogenomics on the design of
strategies and programmes of work to ensure that the resultant studies and
results will be of a high statistical quality.
5. Identify statistical issues and propose resolutions in areas
affecting Clinical Pharmacogenomics.
a. Discuss issues with B&R colleagues active in the Clinical
Pharmacogenomics area at other sites, in particular, with the statistician
associated with the Pharmacogenomics Centre of Emphasis(COE)
b. Monitor literature for relevant developments in statistical methods
for pharmacogenomics and where appropriate, involve the Statistical
Research & Consulting Centre in the development and adoption of new and
improved statistical methods.
6. Share experience and knowledge of statistical matters relating to
Clinical Pharmacogenomics with other statisticians in B&R, both at Sandwich
and at other sites, through internal seminars and project meetings.


Natalie Fforde
Managing Director
Fforde-Management Ltd
Curtis House
34 Third Ave
Hove
BN3 2PD

Tel: 01273 722366
Fax: 01273 325350
Mobile: 07769 700 222
www.fforde-management.com